CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...

With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot happening in the genome editing field. By Amber Dance/Knowable Magazine Published Jan 26, ...

CRISPR is in the process of a BLA for a potential breakthrough drug. The company isn't profitable and is losing its chief operating officer. CRISPR has more than $1.9 billion in cash. It opened ...